معرفی
John Affeldt, MD, is an Associate Professor in the Department of Ophthalmology at Loma Linda University’s School of Medicine. His work focuses on corneal diseases, clinical trials, and genetic aspects of eye disorders, with a particular emphasis on Neurotrophic Keratopathy, corneal dystrophies, and infectious conditions like Herpes Zoster Ophthalmicus. He has led multiple pivotal trials, including roles as Principal Investigator (PI) in studies involving recombinant human nerve growth factor (Cenegermin) and antiviral therapies for ocular conditions.
Dr. Affeldt’s research spans over four decades, with notable contributions in viral ophthalmic diseases, genetic mutation analysis in corneal dystrophies, and the evaluation of medical devices such as lacrimal plugs. He has collaborated on projects funded by the National Eye Institute, ReGen Tree, LLC, Combangio, Inc., and Claris Biotherapeutics, addressing issues like post-herpetic neuralgia and corneal regeneration. His studies also cover trauma-related ocular injuries, including airbag-induced alkali burns and mechanical eye trauma complications.
His current active research includes pivotal trials on anti-viral suppression and ocular surface therapies. Completed projects include analyses of TGFBI gene mutations in corneal amyloidosis and the efficacy of staged punctal occlusion for neurotrophic keratopathy. Dr. Affeldt maintains an active role in both academic publishing and translational research, blending clinical practice with scientific inquiry.
- Grants & Projects:
- Principal Investigator for SEER-2 (Clarion Biotherapeutics), evaluating corneal repair therapies (2024–2025)
- Lead on KPI-012 trials (Combangio, Inc.) for corneal defects post-retinal procedures (2023)
- Investigator in the Zoster Eye Disease Study (ZEDS) for antiviral suppression (2018–2024)
Dr. Affeldt’s research often involves interdisciplinary collaborations, integrating clinical trials with genetic and proteomic studies to address complex ocular pathologies. His work emphasizes both patient care innovations and foundational understanding of corneal diseases.
